Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists

United European Gastroenterology Journal
Martine De VosBelgian Inflammatory Bowel Disease Research and Development (BIRD)

Abstract

Vedolizumab is a recently available monoclonal antibody targeting α4β7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). The objective of this article is to evaluate the efficacy of vedolizumab induction therapy in anti-TNF-refractory/intolerant UC and CD patients in real life. A cohort of 149 moderately to severely active UC and CD patients who failed or showed intolerance to at least two TNF antagonists participated in a medical need program and received vedolizumab in 37 Belgian centers (April-September 2015). Rates of clinical response and remission were retrospectively evaluated at Week 10 for UC and Week 14 for CD using the physician's global assessment (PGA), Mayo score and Harvey Bradshaw index (HBI) or Crohn's disease activity score (CDAI) scores. Eighty-four patients (29 UC, 55 CD) had sufficient data for analysis. For UC patients, clinical response was observed in 76% based on PGA and 59% based on the Mayo score. The corresponding percentages for CD patients were 80% for PGA and 65% for HBI/CDAI. Clinical remission rates were 10% and 40% for UC and CD, respectively. Steroid-free remission was observed in respectively 10% and 35%. Globally, corticosteroids were stopped in 14 out of 48 pat...Continue Reading

References

Mar 8, 1980·Lancet·R F Harvey, J M Bradshaw
Dec 13, 2005·The New England Journal of Medicine·Paul RutgeertsJean Frédéric Colombel
Jul 16, 2008·Inflammatory Bowel Diseases·James D LewisJonas H Ellenberg
Feb 22, 2012·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Christina HaAsher Kornbluth
Aug 24, 2013·The New England Journal of Medicine·Brian G FeaganUNKNOWN GEMINI 1 Study Group
Aug 24, 2013·The New England Journal of Medicine·William J SandbornUNKNOWN GEMINI 2 Study Group
Mar 3, 2015·Therapeutic Advances in Gastroenterology·Aurelien Amiot, Laurent Peyrin-Biroulet
Aug 20, 2015·Inflammatory Bowel Diseases·Edward SheltonVijay Yajnik
Dec 19, 2015·Journal of Crohn's & Colitis·Emily E VivioMatthew A Ciorba
Feb 20, 2016·Gut·Jean-Frédéric ColombelBrian G Feagan
Oct 19, 2016·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Aurelien AmiotUNKNOWN Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif
Apr 3, 2016·Alimentary Pharmacology & Therapeutics·D C BaumgartUNKNOWN Vedolizumab Germany Consortium
Jun 15, 2016·The American Journal of Gastroenterology·Parambir S DulaiJean-Frederic Colombel

❮ Previous
Next ❯

Citations

Apr 2, 2019·Inflammatory Bowel Diseases·Agnese FavaleUNKNOWN Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
Nov 2, 2019·Crohn's & Colitis 360·Bharati KocharMichael D Kappelman
Apr 16, 2020·Journal of Gastroenterology and Hepatology·Renske Wilhelmina Maria PauwelsChristien Janneke van der Woude
Jun 9, 2019·Gastroenterology·Mark LöwenbergGeert D'Haens

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Related Feeds

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Aphasia

Aphasia affects the ability to process language, including formulation and comprehension of language and speech, as well as the ability to read or write. Here is the latest research on aphasia.